Crizotinib is an ATP-competitive inhibitor targeting ALK/ROS1/c-MET kinases that has been approved by the FDA as a first-line chemical for the treatment of NSCLC and other cancers with ALK rearrangement, ROS1 rearrangement, or aberrant activation of c-MET2-5. Here, ALK is linked to non-small cell lung carcinoma.